Basal and fasting/refeeding-regulated tissue levels of endogenous PPAR-α ligands in zucker rats

Obesity

Volumn 18, Issue 1, 2010, Pages 55-62

  Izzo, Angelo A ^a   Piscitelli, Fabiana ^b   Capasso, Raffaele ^a   Marini, Pietro ^b   Cristino, Luigia ^a   Petrosino, Stefania ^b   Di Marzo, Vincenzo ^b  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^b CNR   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ETHANOLAMINE DERIVATIVE; N OLEOYLETHANOLAMINE; N-OLEOYLETHANOLAMINE; PALMIDROL; PALMITIC ACID DERIVATIVE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA;

ADIPOSE TISSUE; ANALYSIS OF VARIANCE; ANIMAL; ANTIBODY SPECIFICITY; ARTICLE; BRAIN STEM; DUODENUM; EATING; ENERGY METABOLISM; FOOD DEPRIVATION; IMAGE PROCESSING; IMMUNOHISTOCHEMISTRY; LIVER; MALE; MASS SPECTROMETRY; METABOLISM; PANCREAS; PHYSIOLOGY; RAT; WISTAR RAT; ZUCKER RAT;

ADIPOSE TISSUE; ANALYSIS OF VARIANCE; ANIMALS; BRAIN STEM; DUODENUM; EATING; ENERGY METABOLISM; ETHANOLAMINES; FOOD DEPRIVATION; IMAGE PROCESSING, COMPUTER-ASSISTED; IMMUNOHISTOCHEMISTRY; LIVER; MALE; MASS SPECTROMETRY; ORGAN SPECIFICITY; PALMITIC ACIDS; PANCREAS; PPAR ALPHA; RATS; RATS, WISTAR; RATS, ZUCKER;

RATTUS;

EID: 73949083905     PISSN: 19307381     EISSN: 1930739X     Source Type: Journal    
DOI: 10.1038/oby.2009.186     Document Type: Article

References (59)

1. Staels B, Maes M, Zambon A. Fibrates and future PPARalpha agonists in the treatment of cardiovascular disease. Nat Clin Pract Cardiovasc Med 2008;5:542-553.
2. Yu S, Rao S, Reddy JK. Peroxisome proliferator-activated receptors, fatty acid oxidation, steatohepatitis and hepatocarcinogenesis. Curr Mol Med 2003;3:561-572.
3. Cho MC, Lee K, Paik SG, Yoon DY. Peroxisome Proliferators-Activated Receptor (PPAR) Modulators and Metabolic Disorders. PPAR Res 2008;2008:679137.
4. Chou CJ, Haluzik M, Gregory C et al. WY14,643, a peroxisome proliferator-activated receptor alpha (PPARalpha) agonist, improves hepatic and muscle steatosis and reverses insulin resistance in lipoatrophic A-ZIP/F-1 mice. J Biol Chem 2002;277:24484-24489.
5. Tsunoda M, Kobayashi N, Ide T et al. A novel PPARalpha agonist ameliorates insulin resistance in dogs fed a high-fat diet. Am J Physiol Endocrinol Metab 2008;294:E833-E840.
6. Chinetti-Gbaguidi G, Fruchart JC, Staels B. Pleiotropic effects of fibrates. Curr Atheroscler Rep 2005;7:396-401.
7. Zandbergen F, Plutzky J. PPARalpha in atherosclerosis and inflammation. Biochim Biophys Acta 2007;1771:972-982.
8. Srivastava RA, Jahagirdar R, Azhar S, Sharma S, Bisgaier CL. Peroxisome proliferator-activated receptor-alpha selective ligand reduces adiposity, improves insulin sensitivity and inhibits atherosclerosis in LDL receptor-deficient mice. Mol Cell Biochem 2006;285:35-50.
9. Fu J, Gaetani S, Oveisi F et al. Oleylethanolamide regulates feeding and body weight through activation of the nuclear receptor PPAR-alpha. Nature 2003;425:90-93.
10. Lo Verme J, Fu J, Astarita G et al. The nuclear receptor peroxisome proliferator-activated receptor-alpha mediates the anti-inflammatory actions of palmitoylethanolamide. Mol Pharmacol 2005;67:15-19.
11. Gaetani S, Kaye WH, Cuomo V, Piomelli D. Role of endocannabinoids and their analogues in obesity and eating disorders. Eat Weight Disord 2008;13:e42-e48.
12. Thabuis C, Tissot-Favre D, Bezelgues JB et al. Biological functions and metabolism of oleoylethanolamide. Lipids 2008;43:887-894.
13. Rodríguez de Fonseca F, Navarro M, Gómez R et al. An anorexic lipid mediator regulated by feeding. Nature 2001;414:209-212.
14. Yang Y, Chen M, Georgeson KE, Harmon CM. Mechanism of oleoylethanolamide on fatty acid uptake in small intestine after food intake and body weight reduction. Am J Physiol Regul Integr Comp Physiol 2007;292:R235-R241.
15. Schwartz GJ, Fu J, Astarita G et al. The lipid messenger OEA links dietary fat intake to satiety. Cell Metab 2008;8:281-288.
16. Guzmán M, Lo Verme J, Fu J et al. Oleoylethanolamide stimulates lipolysis by activating the nuclear receptor peroxisome proliferator-activated receptor alpha (PPAR-alpha). J Biol Chem 2004;279:27849-27854.
17. Fu J, Oveisi F, Gaetani S, Lin E, Piomelli D. Oleoylethanolamide, an endogenous PPAR-alpha agonist, lowers body weight and hyperlipidemia in obese rats. Neuropharmacology 2005;48:1147-1153.
18. González-Yanes C, Serrano A, Bermúdez-Silva FJ et al. Oleylethanolamide impairs glucose tolerance and inhibits insulin-stimulated glucose uptake in rat adipocytes through p38 and JNK MAPK pathways. Am J Physiol Endocrinol Metab 2005;289:E923-E929.
19. Ropero AB, Juan-Picó P, Rafacho A et al. Rapid non-genomic regulation of Ca2+ signals and insulin secretion by PPAR alpha ligands in mouse pancreatic islets of Langerhans. J Endocrinol 2009;200:127-138.
20. Hoareau L, Ravanan P, Gonthier MP et al. Effect of PEA on LPS inflammatory action in human adipocytes. Cytokine 2006;34:291-296.
21. Hoareau L, Buyse M, Festy F et al. Anti-inflammatory effect of palmitoylethanolamide on human adipocytes. Obesity (Silver Spring) 2009;17:431-438.
22. Di Marzo V. CB(1) receptor antagonism: biological basis for metabolic effects. Drug Discov Today 2008;13:1026-1041.
23. Matias I, Gonthier M P, Petrosino S et al. Role and regulation of acylethanolamides in energy balance: focus on adipocytes and beta-cells. Br J Pharmacol 2007;152:676-690.
24. Fu J, Astarita G, Gaetani S et al. Food intake regulates oleoylethanolamide formation and degradation in the proximal small intestine. J Biol Chem 2007;282:1518-1528.
25. Gómez R, Navarro M, Ferrer B et al. A peripheral mechanism for CB1 cannabinoid receptor-dependent modulation of feeding. J Neurosci 2002;22:9612-9617.
26. Artmann A, Petersen G, Hellgren LI et al. Influence of dietary fatty acids on endocannabinoid and N-acylethanolamine levels in rat brain, liver and small intestine. Biochim Biophys Acta 2008;1781:200-212.
27. De Petrocellis L, Di Marzo V. An introduction to the endocannabinoid system: from the early to the latest concepts. Best Pract Res Clin Endocrinol Metab 2009;23:1-15.
28. Izzo AA, Piscitelli F, Capasso R et al. Peripheral endocannabinoid dysregulation in obesity: relation to intestinal motility and energy processing induced by food deprivation and re-feeding. Br J Pharmacol 2009; e-pub ahead of print 3 April 2009.
29. Zhou Y T, Shimabukuro M, Wang MY et al. Role of peroxisome proliferator-activated receptor alpha in disease of pancreatic beta cells. Proc Natl Acad Sci USA 1998;95:8898-8903.
30. Dana SL, Hoener PA, Bilakovics JM et al. Peroxisome proliferator- activated receptor subtype-specific regulation of hepatic and peripheral gene expression in the Zucker diabetic fatty rat. Metab Clin Exp 2001;50:963-971.
31. Reifel-Miller A, Otto K, Hawkins E et al. A peroxisome proliferator-activated receptor alpha/gamma dual agonist with a unique in vitro profile and potent glucose and lipid effects in rodent models of type 2 diabetes and dyslipidemia. Mol Endocrinol 2005;19:1593-1605.
32. Lanne B, Dahllöf B, Lindahl C et al. PPARalpha and PPARgamma regulation of liver and adipose proteins in obese and dyslipidemic rodents. J Proteome Res 2006;5:1850-1859.
33. Petersen G, Sørensen C, Schmid PC et al. Intestinal levels of anandamide and oleoylethanolamide in food-deprived rats are regulated through their precursors. Biochim Biophys Acta 2006;1761:143-50; discussion 141.
34. D'Agostino G, La Rana G, Russo R et al. Acute intracerebroventricular administration of palmitoylethanolamide, an endogenous peroxisome proliferator-activated receptor-alpha agonist, modulates carrageenan-induced paw edema in mice. J Pharmacol Exp Ther 2007;322: 1137-1143.
35. Re G, Barbero R, Miolo A, Di Marzo V. Palmitoylethanolamide, endocannabinoids and related cannabimimetic compounds in protection against tissue inflammation and pain: potential use in companion animals. Vet J 2007;173:21-30.
36. Gorla-Bajszczak A, Siegrist-Kaiser C, Boss O, Burger AG, Meier CA. Expression of peroxisome proliferator-activated receptors in lean and obese Zucker rats. Eur J Endocrinol 2000;142:71-78.
37. Oana F, Takeda H, Hayakawa K et al. Physiological difference between obese (fa/fa) Zucker rats and lean Zucker rats concerning adiponectin. Metab Clin Exp 2005;54:995-1001.
38. Escher P, Braissant O, Basu-Modak S et al. Rat PPARs: quantitative analysis in adult rat tissues and regulation in fasting and refeeding. Endocrinology 2001;142:4195-4202.
39. Young ME, Guthrie PH, Razeghi P et al. Impaired long-chain fatty acid oxidation and contractile dysfunction in the obese Zucker rat heart. Diabetes 2002;51:2587-2595.
40. Fu J, Kim J, Oveisi F, Astarita G, Piomelli D. Targeted enhancement of oleoylethanolamide production in proximal small intestine induces across-meal satiety in rats. Am J Physiol Regul Integr Comp Physiol 2008; 295:R45-R50.
41. Serrano A, Del Arco I, Javier Pavón F et al. The cannabinoid CB1 receptor antagonist SR141716A (Rimonabant) enhances the metabolic benefits of long-term treatment with oleoylethanolamide in Zucker rats. Neuropharmacology 2008;54:226-234.
42. Aviello G, Matias I, Capasso R et al. Inhibitory effect of the anorexic compound oleoylethanolamide on gastric emptying in control and overweight mice. J Mol Med 2008;86:413-422.
43. Gulaya NM, Kuzmenko AI, Margitich VM et al. Long-chain N-acylethanolamines inhibit lipid peroxidation in rat liver mitochondria under acute hypoxic hypoxia. Chem Phys Lipids 1998;97:49-54.
44. Petrosino S, Palazzo E, de Novellis V et al. Changes in spinal and supraspinal endocannabinoid levels in neuropathic rats. Neuropharmacology 2007;52:415-422.
45. Maione S, De Petrocellis L, de Novellis V et al. Analgesic actions of N-arachidonoyl-serotonin, a fatty acid amide hydrolase inhibitor with antagonistic activity at vanilloid TRPV1 receptors. Br J Pharmacol 2007;150:766-781.
46. Darmani NA, Izzo AA, Degenhardt B et al. Involvement of the cannabimimetic compound, N-palmitoyl-ethanolamine, in inflammatory and neuropathic conditions: review of the available pre-clinical data, and first human studies. Neuropharmacology 2005;48:1154-1163.
47. D'Argenio G, Petrosino S, Gianfrani C et al. Overactivity of the intestinal endocannabinoid system in celiac disease and in methotrexate-treated rats. J Mol Med 2007;85:523-530.
48. Loría F, Petrosino S, Mestre L et al. Study of the regulation of the endocannabinoid system in a virus model of multiple sclerosis reveals a therapeutic effect of palmitoylethanolamide. Eur J Neurosci 2008;28:633-641.
49. Garcia-Ovejero D, Arevalo-Martin A, Petrosino S et al. The endocannabinoid system is modulated in response to spinal cord injury in rats. Neurobiol Dis 2009;33:57-71.
50. Leung D, Saghatelian A, Simon GM, Cravatt B F. Inactivation of N-acyl phosphatidylethanolamine phospholipase D reveals multiple mechanisms for the biosynthesis of endocannabinoids. Biochemistry 2006;45:4720-4726.
51. Jo YH, Chen YJ, Chua SC Jr, Talmage DA, Role LW. Integration of endocannabinoid and leptin signaling in an appetite-related neural circuit. Neuron 2005;48:1055-1066.
52. Maccarrone M, Di Rienzo M, Finazzi-Agrò A, Rossi A. Leptin activates the anandamide hydrolase promoter in human T lymphocytes through STAT3. J Biol Chem 2003;278:13318-13324.
53. Waleh NS, Cravatt B F, Apte-Deshpande A, Terao A, Kilduff TS. Transcriptional regulation of the mouse fatty acid amide hydrolase gene. Gene 2002;291:203-210.
54. Malcher-Lopes R, Di S, Marcheselli VS et al. Opposing crosstalk between leptin and glucocorticoids rapidly modulates synaptic excitation via endocannabinoid release. J Neurosci 2006;26:6643-6650.
55. Murdolo G, Kempf K, Hammarstedt A et al. Insulin differentially modulates the peripheral endocannabinoid system in human subcutaneous abdominal adipose tissue from lean and obese individuals. J Endocrinol Invest 2007;30:RC17-RC21.
56. Kola B, Farkas I, Christ-Crain M et al. The orexigenic effect of ghrelin is mediated through central activation of the endogenous cannabinoid system. PLoS ONE 2008;3:e1797.
57. Berger A, Crozier G, Bisogno T et al. Anandamide and diet: inclusion of dietary arachidonate and docosahexaenoate leads to increased brain levels of the corresponding N-acylethanolamines in piglets. Proc Natl Acad Sci USA 2001;98:6402-6406.
58. Matias I, Léonhardt M, Lesage J et al. Effect of maternal under-nutrition on pup body weight and hypothalamic endocannabinoid levels. Cell Mol Life Sci 2003;60:382-389.
59. Matias I, Carta G, Murru E et al. Effect of polyunsaturated fatty acids on endocannabinoid and N-acyl-ethanolamine levels in mouse adipocytes. Biochim Biophys Acta 2008;1781:52-60.